Even if the Angleman syndrome market share is reduced to 30% c/o Ultragenyx as a worst case scenario, that's still a potential pool of 4800 US patients needing treatment. Neuren is still very much in the game regardless, and a positive Angleman P2 result will (for me at least) confirm platform drug status and offer an alternative to Ultragenyx and Co. The pressure mounts...
Even if the Angleman syndrome market share is reduced to 30% c/o...
-
- There are more pages in this discussion • 448 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
-0.040(0.26%) |
Mkt cap ! $1.990B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.20 | $8.124M | 524.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 64 | $15.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.58 | 597 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |